Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016
Published Jul 27, 2016
131 pages — Published Jul 27, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
- The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects
- The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising

  
Source:
Document ID
GMDHC8303IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Hospital Acquired Pneumonia (HAP) Overview91
Therapeutics Development102
  Pipeline Products for Hospital Acquired Pneumonia (HAP) Overview101
  Pipeline Products for Hospital Acquired Pneumonia (HAP) Comparative Analysis111
Hospital Acquired Pneumonia (HAP) Therapeutics under Development by Companies122
Hospital Acquired Pneumonia (HAP) Therapeutics under Investigation by Universities/Institutes141
Hospital Acquired Pneumonia (HAP) Pipeline Products Glance154
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
  Unknown Stage Products181
Hospital Acquired Pneumonia (HAP) Products under Development by Companies193
Hospital Acquired Pneumonia (HAP) Products under Investigation by Universities/Institutes221
Hospital Acquired Pneumonia (HAP) Companies Involved in Therapeutics Development2318
  Achaogen Inc.231
  Adenium Biotech ApS241
  Aridis Pharmaceuticals LLC251
  AstraZeneca Plc261
  Bayer AG271
  Cardeas Pharma Corp.281
  MedImmune, LLC291
  Meiji Seika Pharma Co., Ltd.301
  Melinta Therapeutics, Inc311
  Merck &Co., Inc.321
  Motif Bio Plc331
  Nabriva Therapeutics AG341
  Savara Inc.351
  Sealife PHARMA GMBH361
  Shionogi &Co., Ltd.371
  Tetraphase Pharmaceuticals Inc.381
  Wockhardt Limited391
  Zavante Therapeutics, Inc.401
Hospital Acquired Pneumonia (HAP) Therapeutics Assessment4110
  Assessment by Monotherapy Products411
  Assessment by Combination Products421
  Assessment by Target432
  Assessment by Mechanism of Action452
  Assessment by Route of Administration472
  Assessment by Molecule Type492
Drug Profiles5169
  (amikacin sulfate + fosfomycin) Drug Profile512
  (avibactam + ceftazidime) Drug Profile534
  (ceftolozane sulfate + tazobactam sodium) Drug Profile575
  (cilastatin sodium + imipenem + relebactam) Drug Profile621
  (Pseudomonas + ventilator associated pneumonia) vaccine Drug Profile631
  AA-139 Drug Profile641
  Aerucin Drug Profile651
  amikacin sulfate Drug Profile662
  arbekacin Drug Profile681
  cefepime + zidebactam Drug Profile691
  delafloxacin Drug Profile708
  eravacycline Drug Profile786
  fosfomycin tromethamine Drug Profile842
  iclaprim mesylate Drug Profile863
  lefamulin acetate Drug Profile893
  MEDI-3902 Drug Profile921
  MEDI-4893 Drug Profile931
  Nu-2 Drug Profile941
  PAC-I Drug Profile951
  Panaecin Drug Profile961
  panobacumab Drug Profile971
  plazomicin sulfate Drug Profile984
  Qn-2251 Drug Profile1021
  S-649266 Drug Profile1032
  SLP-0905 Drug Profile1051
  tedizolid phosphate Drug Profile1067
  tosatoxumab Drug Profile1132
  vancomycin hydrochloride Drug Profile1153
  WCK-2349 Drug Profile1181
  WCK-771 Drug Profile1191
Hospital Acquired Pneumonia (HAP) Dormant Projects1201
Hospital Acquired Pneumonia (HAP) Discontinued Products1211
Hospital Acquired Pneumonia (HAP) Product Development Milestones1228
  Featured News &Press Releases1221
    Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections1221
    Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe1221
    Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets1231
    Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia1241
    Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured1241
    Oct 13, 2015: Motif Bio Announces Results of Two Posters on Iclaprim at ID Week 20151241
    Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 20151251
    Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia1261
    Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA1271
    Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline s Potential Activity in Treating Serious Respiratory Infections1271
    Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 20131282
Appendix1302
  Methodology1301
  Coverage1301
  Secondary Research1301
  Primary Research1301
  Expert Panel Validation1301
  Contact Us1301
  Disclaimer1311

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hospital-Acquired-Pneumonia-HAP-Pipeline-Review-H2-2016-2088-16267>
  
APA:
Global Markets Direct - Market Research. (2016). Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hospital-Acquired-Pneumonia-HAP-Pipeline-Review-H2-2016-2088-16267>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.